Liersch, Torsten

[["dc.bibliographiccitation.artnumber","27"],["dc.bibliographiccitation.journal","World Journal of Surgical Oncology"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T08:44:09Z"],["dc.date.available","2018-11-07T08:44:09Z"],["dc.date.issued","2010"],["dc.description.abstract","Background: Response to preoperative radiochemotherapy (RCT) in patients with locally advanced rectal cancer is very heterogeneous. Pathologic complete response (pCR) is accompanied by a favorable outcome. However, most patients show incomplete response. The aim of this investigation was to find indications for risk stratification in the group of intermediate responders to RCT. Methods: From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied. Surgical treatment comprised curative (R0) total mesorectal excision (TME) in all cases. In 95 patients available for statistical analyses, residual transmural infiltration of the mesorectal compartment, nodal involvement and histolologic tumor grading were investigated for their prognostic impact on disease-free (DFS) and overall survival ( OS). Results: Residual tumor transgression into the mesorectal compartment (ypT3) did not influence DFS and OS rates ( p = 0.619, p = 0.602, respectively). Nodal involvement after preoperative RCT (ypN1/2) turned out to be a valid prognostic factor with decreased DFS and OS (p = 0.0463, p = 0.0236, respectively). Persistent tumor infiltration of the mesorectum ( ypT3) and histologic tumor grading of residual tumor cell clusters were strongly correlated with lymph node metastases after neoadjuvant treatment (p < 0.001). Conclusions: Advanced transmural tumor invasion after RCT does not affect prognosis when curative ( R0) resection is achievable. Residual nodal status is the most important predictor of individual outcome in intermediate responders to preoperative RCT. Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors. Future clinical trials for risk-adapted adjuvant therapy should be based on a synopsis of clinicopathologic parameters."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft"],["dc.identifier.doi","10.1186/1477-7819-8-27"],["dc.identifier.isi","000277431000001"],["dc.identifier.pmid","20388220"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5680"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20132"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1477-7819"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","48"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Radiotherapy and Oncology"],["dc.bibliographiccitation.lastpage","54"],["dc.bibliographiccitation.volume","108"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Merkel, Susanne"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Raab, Hans-Rudolf"],["dc.contributor.author","Tschmelitsch, Joerg"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Wittekind, Christian"],["dc.contributor.author","Sauer, Rolf"],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:22:42Z"],["dc.date.available","2018-11-07T09:22:42Z"],["dc.date.issued","2013"],["dc.description.abstract","Introduction: The CAO/ARO/AIO-94 phase-III-trial demonstrated a significant improvement of preoperative chemoradiotherapy (CRT) versus postoperative CRT on local control for UICC stage II/III rectal cancer patients, but no effect on long-term survival. In this add-on evaluation, we investigated the association of gender and age with acute toxicity and outcome. Patients and methods: According to actual treatment analyses, 654 of 799 patients had received pre-(n = 406) or postoperative CRT (n = 248); in 145 patients postoperative CRT was not applied. Gender, age and clinicopathological parameters were correlated with CRT-associated acute toxicity and survival. Results: The 10-year survival was higher in women than in men, with 72.4% versus 65.6% for time to recurrence (p = 0.088) and 62.7% versus 58.4% for overall-survival (OS) (p = 0.066), as expected. For patients receiving CRT, women showed higher hematologic (p < 0.001) and acute organ toxicity (p < 0.001) in the entire cohort as well as in subgroup analyses according to pre- (p = 0.016) and postoperative CRT (p < 0.001). Lowest OS was seen in patients without acute toxicity (p = 0.0271). Multivariate analyses for OS showed that acute organ toxicity (p = 0.034) was beneficial while age (p < 0.001) was associated with worse OS. Discussion: Female gender is significantly associated with CRT-induced acute toxicity in rectal cancer. Acute toxicity during CRT may be associated with improved long-term outcome. (C) 2013 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.radonc.2013.05.009"],["dc.identifier.isi","000324155900007"],["dc.identifier.pmid","23768685"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11335"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29411"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","0167-8140"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: Long-term results of the German CAO/ARO/AIO-94 phase III trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","633"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Langenbeck s Archives of Surgery"],["dc.bibliographiccitation.lastpage","641"],["dc.bibliographiccitation.volume","395"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T08:40:58Z"],["dc.date.available","2018-11-07T08:40:58Z"],["dc.date.issued","2010"],["dc.description.abstract","We evaluated individualized multimodal oncological strategies in patients with bilobular colorectal liver metastases (biCRC-LM) as well as their effect on R0 resection rates, disease-free survival (DFS), and overall survival (OS). Between January 2001 and December 2008, 64 patients were assigned to straightforward or two-stage liver resection +/- preoperative 5-fluorouracil (5FU)-based chemotherapy (CTx). Postoperative strategy after R0-resection was either \"wait and see\" or \"adjuvant\" therapy (3 cycles of CTx or anti-carcinoembryonic antigen (CEA)-radioimmunotherapy with (131)I-labetuzumab in a dose of 40-50 mCi/m(2)). Forty-three initially unresectable patients received preoperative CTx for downsizing of their biCRC-LM. Straightforward or two-stage liver resection was intended in 40 and 24 patients, respectively. Histopathologically confirmed R0-liver resection could be achieved in 47 patients. Surgical morbidity and mortality rates were 33% and 1.5%, respectively. Postoperatively, 26 patients received anti-cancer therapy (5 x CTx, 21 x anti-CEA-radioimmunotherapy). After R0-liver resection, median OS was significantly better compared to R1/R2 resections followed by palliative 5FU-CTx (38 versus 19 months, p = 0.035). There was no significant difference in DFS (p = 0.650) and OS (p = 0.435) between straightforward and two-stage liver resection. Compared to \"wait and see\" strategy, the application of postoperative therapy in adjuvant intent was associated with a better OS (p = 0.048). Extensive liver resection within multimodal treatment concepts is justified in patients with biCRC-LM when complete resection of all metastases seems to be achievable."],["dc.identifier.doi","10.1007/s00423-010-0604-7"],["dc.identifier.isi","000280241200005"],["dc.identifier.pmid","20213463"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4991"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19362"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1435-2443"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Multimodal treatment options for bilobar colorectal liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","451"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Langenbeck s Archives of Surgery"],["dc.bibliographiccitation.lastpage","458"],["dc.bibliographiccitation.volume","395"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Gunawan, Bastian"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Szoeke, R."],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T08:44:42Z"],["dc.date.available","2018-11-07T08:44:42Z"],["dc.date.issued","2010"],["dc.description.abstract","The prognosis of patients with pancreatic cancer remains poor, even after potentially curative R0 resection. This discrepancy may be due to the histopathological misclassification of R1 cases as curative resections (R0) in the past. To test this hypothesis, color coding of all resection margins and organ surfaces as part of a standardized histopathological workup was implemented and prospectively tested on 100 pancreatic head specimens. Thirty-five patients were excluded from the analysis owing to the pathohistological diagnosis; only pancreatic ductal adenocarcinoma, distal bile duct adenocarcinoma, and periampullary adenocarcinoma were included. Applying the International Union Against Cancer criteria, 32 cancer resections were classified R0 (49.2%), while 33 cases turned out to be R1 resections (50.8%). The mesopancreas was infiltrated in 22 of the 33 R1 resection specimens (66.6%). It proved to be the only site of tumor infiltration in 17 specimens (51.5%). Applying the Royal College of Pathologists' criteria, 46 resections were classified R1 (70.8%). As expected, the mesopancreas again was the most frequent site of noncurative resection (n = 27; 58.7%). Using the intensified histopathological workup for pancreatic head cancer specimens resulted in an increased rate of R1 resections and the mesopancreas represents the primary site for positive resection margins. Such results are of relevance for patients' stratification in clinical trials."],["dc.identifier.doi","10.1007/s00423-009-0494-8"],["dc.identifier.isi","000276261200023"],["dc.identifier.pmid","19418067"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4177"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20262"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1435-2443"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","309"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Clinical & Experimental Metastasis"],["dc.bibliographiccitation.lastpage","323"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Menck, Kerstin"],["dc.contributor.author","Schmick, Nadine Annette"],["dc.contributor.author","Schubert, Antonia"],["dc.contributor.author","Rietkoetter, Eva"],["dc.contributor.author","Arackal, Jetcy"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Schambony, Alexandra"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Klemm, Florian"],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Pukrop, Tobias"],["dc.date.accessioned","2018-11-07T10:16:24Z"],["dc.date.available","2018-11-07T10:16:24Z"],["dc.date.issued","2016"],["dc.description.abstract","Liver metastasis development in breast cancer patients is common and confers a poor prognosis. So far, the prognostic significance of surgical resection and clinical relevance of biomarker analysis in metastatic tissue have barely been investigated. We previously demonstrated an impact of WNT signaling in breast cancer brain metastasis. This study aimed to investigate the value of established prognostic markers and WNT signaling components in liver metastases. Overall N = 34 breast cancer liver metastases (with matched primaries in 19/34 cases) were included in this retrospective study. Primaries and metastatic samples were analyzed for their expression of the estrogen (ER) and progesterone receptor, HER-2, Ki67, and various WNT signaling-components by immunohistochemistry. Furthermore, beta-catenin-dependent and -independent WNT scores were generated and analyzed for their prognostic value. Additionally, the influence of the alternative WNT receptor ROR on signaling and invasiveness was analyzed in vitro. ER positivity (HR 0.09, 95 % CI 0.01-0.56) and high Ki67 (HR 3.68, 95 % CI 1.12-12.06) in the primaries had prognostic impact. However, only Ki67 remained prognostic in the metastatic tissue (HR 2.46, 95 % CI 1.11-5.44). Additionally, the beta-catenin-independent WNT score correlated with reduced overall survival only in the metastasized situation (HR 2.19, 95 % CI 1.02-4.69, p = 0.0391). This is in line with the in vitro results of the alternative WNT receptors ROR1 and ROR2, which foster invasion. In breast cancer, the value of prognostic markers established in primary tumors cannot directly be translated to metastases. Our results revealed beta-catenin-independent WNT signaling to be associated with poor prognosis in patients with breast cancer liver metastasis."],["dc.identifier.doi","10.1007/s10585-016-9780-3"],["dc.identifier.isi","000373005900002"],["dc.identifier.pmid","26862065"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13177"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41033"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1573-7276"],["dc.relation.issn","0262-0898"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","beta-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1229"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Cancer"],["dc.bibliographiccitation.lastpage","1237"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Rühlmann, Felix"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.date.accessioned","2018-11-07T10:28:34Z"],["dc.date.available","2018-11-07T10:28:34Z"],["dc.date.issued","2017"],["dc.description.abstract","The cellular sarcoma gene (SRC) is a proto-oncogene encoding for a tyrosine kinase. SRC expression was determined in locally advanced rectal adenocarcinoma tissue from pretreatment biopsies and resection specimens. The expression level was correlated with clinicopathological parameters to evaluate the predictive and prognostic capacity. For this monocentric analysis 186 patients with locally advanced rectal cancer (median: 63.7 years; 130 men (69.9%), 56 women (30.1%)) were included. Patients with a carcinoma of the upper third of the rectum were treated with primary tumor resection (n=27; 14.5%). All other patients received a preoperative chemoradiotherapy (CRT) with 50.4 Gy and concomitant 5-fluorouracil (5-FU) or 5-FU+oxaliplatin followed by postoperative chemotherapy with 5-FU or 5-FU+ oxaliplatin. SRC expression was determined with immunohistochemical staining from pretreatment biopsies (n=152) and residual tumor tissue from the resection specimens (n=163). The results were correlated with clinicopathological parameters and long-term follow-up. The expression of SRC was determined in pretherapeutic biopsies (mean H-Score: 229) and resection specimens (mean H-Score: 254). High SRC expression in pretherapeutic tumor samples significantly correlated with a negative postoperative nodal status (p=0.005). Furthermore an increased protein expression in residual tumor tissue was associated with fewer distant metastases (p=0.04). The overexpression of SRC in pretreatment tumor biopsies showed also a trend for a longer cancer-specific survival (CSS; p=0.05) and fewer local relapses (p=0.06) during long-term follow-up. High SRC expression in rectal cancer seems to be associated with a better long-term outcome. This finding could help in the future to stratify patients for a recurrence risk adapted postoperative treatment."],["dc.identifier.doi","10.7150/jca.16980"],["dc.identifier.isi","000402474000015"],["dc.identifier.pmid","28607598"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14945"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43450"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Ivyspring Int Publ"],["dc.relation.issn","1837-9664"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.lastpage","31"],["dc.bibliographiccitation.volume","34 Suppl 3"],["dc.contributor.author","Arnold, Dirk"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Hegewisch-Becker, Susanna"],["dc.contributor.author","Höhler, Thomas"],["dc.contributor.author","Knoefel, Wolfram Trudo"],["dc.contributor.author","Kubicka, Stefan"],["dc.contributor.author","Lang, Hauke"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Luster, Markus"],["dc.contributor.author","Oettle, Helmut"],["dc.contributor.author","Reinacher-Schick, Anke"],["dc.contributor.author","Ridwelski, Karsten"],["dc.contributor.author","Riess, Hanno"],["dc.contributor.author","Rödel, Claus"],["dc.contributor.author","Rüschoff, Josef"],["dc.contributor.author","Schmiegel, Wolff"],["dc.contributor.author","Schmoll, Hans-Joachim"],["dc.contributor.author","Vanhoefer, Udo"],["dc.date.accessioned","2019-07-09T11:53:49Z"],["dc.date.available","2019-07-09T11:53:49Z"],["dc.date.issued","2011"],["dc.description.abstract","Der XI. Interdisziplinäre Expertenworkshop «Gastrointestinale Tumore», an dem 19 Vertreter der Fachbereiche internistische Onkologie, Gastroenterologie, Strahlentherapie, Chirurgie, Nuklearmedizin und Pathologie teilnahmen, bot einen Überblick über den aktuellen Stand der Wissenschaft im Bereich der gastrointestinalen Karzinome, wobei der Schwerpunkt auf dem Kolon-/Rektum- und Magenkarzinom lag, da in diesen Bereichen die meisten neuen Entwicklungen zu verzeichnen waren. Der Workshop versteht sich als ein interaktives Diskussionsforum zur aktuellen Standortbestimmung von Diagnostik und Therapie sowie zur Thesengenerierung für neue wissenschaftliche und therapeutische Ansätze. Schwerpunkte der diesjährigen Veranstaltung waren zum einen die adjuvante Therapie des Kolonkarzinoms und die First-Line-Therapie des metastasierten kolorektalen Karzinoms, denn in diesen Indikationen haben neue Studiendaten jetzt eine weitere Klärung des Therapiealgorithmus herbeigeführt. Darüber hinaus war die perioperative Therapie bei Lebermetastasen ein wichtiges Thema, zu dem aktuelle Studienkonzepte vorgestellt wurden. Des Weiteren wurde die HER2- Diagnostik beim Magenkarzinom intensiv diskutiert, denn diese unterscheidet sich deutlich von der beim Mammakarzinom. Bei korrekter Diagnostik ist das HER2-positive Magenkarzinom offenbar deutlich weiter verbreitet als bisher angenommen. Viel Beachtung fanden auch die Ergebnisse von 2 aktuellen Phase-III-Studien beim Pankreaskarzinom, die das therapeutische Vorgehen verändern werden und erstmals seit langem einen Fortschritt bei diesem schwer therapierbaren Tumor bedeuten dürften. Die wichtigsten Ergebnisse der 2-tägigen Diskussionsrunde sind im vorliegenden Supplement zusammengefasst."],["dc.identifier.doi","10.1159/000328047"],["dc.identifier.fs","582631"],["dc.identifier.pmid","21577036"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8060"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60502"],["dc.language.iso","de"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1423-0240"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.mesh","Clinical Trials as Topic"],["dc.subject.mesh","Evidence-Based Medicine"],["dc.subject.mesh","Gastrointestinal Neoplasms"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Interdisciplinary Studies"],["dc.subject.mesh","Medical Oncology"],["dc.title","Gastrointestinal tumors-interdisciplinary discussion over new data"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","609"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Case reports in oncology"],["dc.bibliographiccitation.lastpage","615"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Quack, Henriette"],["dc.contributor.author","Erpenbeck, Luise"],["dc.contributor.author","Wolff, Hendrik A."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Seitz, Cornelia S."],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Neumann, Steffen"],["dc.contributor.author","Stanek, Kathrin"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Michels, Beate"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.date.accessioned","2019-07-09T11:40:06Z"],["dc.date.available","2019-07-09T11:40:06Z"],["dc.date.issued","2013-09-01"],["dc.description.abstract","Leukocytoclastic vasculitis is a multicausal systemic inflammatory disease of the small vessels, histologically characterized by inflammation and deposition of both nuclear debris and fibrin in dermal postcapillary venules. The clinical picture typically involves palpable purpura of the lower legs and may be associated with general symptoms such as fatigue, arthralgia and fever. Involvement of the internal organs, most notably the kidneys, the central nervous system or the eyes, is possible and determines the prognosis. Oxaliplatin-induced leukocytoclastic vasculitis is a very rare event that limits treatment options in affected patients. We report 2 patients who developed the condition under chemotherapy for advanced rectal and metastatic colon carcinoma, respectively; a termination of the therapy was therefore necessary. While current therapies for colorectal cancer include the combination of multimodal treatment with new and targeted agents, rare and unusual side effects elicited by established agents also need to be taken into account for the clinical management."],["dc.identifier.doi","10.1159/000357166"],["dc.identifier.fs","601879"],["dc.identifier.pmid","24474925"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10665"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58092"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1662-6575"],["dc.rights","CC BY-NC 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/3.0"],["dc.title","Oxaliplatin-Induced Leukocytoclastic Vasculitis under Adjuvant Chemotherapy for Colorectal Cancer: Two Cases of a Rare Adverse Event."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e101563"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","PLOS ONE"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Ilgen, Peter"],["dc.contributor.author","Stoldt, Stefan"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Wurm, Christian Andreas"],["dc.contributor.author","Rüschoff, Josef"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Jakobs, Stefan"],["dc.date.accessioned","2017-09-07T11:45:42Z"],["dc.date.available","2017-09-07T11:45:42Z"],["dc.date.issued","2014"],["dc.description.abstract","Formalin fixed and paraffin-embedded human tissue resected during cancer surgery is indispensable for diagnostic and therapeutic purposes and represents a vast and largely unexploited resource for research. Optical microscopy of such specimen is curtailed by the diffraction-limited resolution of conventional optical microscopy. To overcome this limitation, we used STED super-resolution microscopy enabling optical resolution well below the diffraction barrier. We visualized nanoscale protein distributions in sections of well-annotated paraffin-embedded human rectal cancer tissue stored in a clinical repository. Using antisera against several mitochondrial proteins, STED microscopy revealed distinct sub-mitochondrial protein distributions, suggesting a high level of structural preservation. Analysis of human tissues stored for up to 17 years demonstrated that these samples were still amenable for super-resolution microscopy. STED microscopy of sections of HER2 positive rectal adenocarcinoma revealed details in the surface and intracellular HER2 distribution that were blurred in the corresponding conventional images, demonstrating the potential of super-resolution microscopy to explore the thus far largely untapped nanoscale regime in tissues stored in biorepositories."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2014"],["dc.identifier.doi","10.1371/journal.pone.0101563"],["dc.identifier.gro","3142087"],["dc.identifier.isi","000339992400018"],["dc.identifier.pmid","25025184"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10481"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/4400"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","STED Super-Resolution Microscopy of Clinical Paraffin-Embedded Human Rectal Cancer Tissue"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2442"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Annals of Surgical Oncology"],["dc.bibliographiccitation.lastpage","2452"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T08:52:40Z"],["dc.date.available","2018-11-07T08:52:40Z"],["dc.date.issued","2011"],["dc.description.abstract","For years, 5-fluorouracil (5-FU) has been the backbone of radiochemotherapy (RCT) of locally advanced rectal cancer. Its main target, thymidylate synthase (TS), is speculated to be an important biomarker for response prediction and long-term prognosis. In this study, we analyzed TS expression in the rectal cancer tissue of 208 patients to evaluate its predictive/prognostic potential. All patients included were diagnosed with locally advanced adenocarcinoma of the rectum (UICC II and III) and were treated within randomized clinical trials of the German Rectal Cancer Study Group. Preoperative RCT (50.4 Gy and concomitant either 5-FU or 5-FU and oxaliplatin) was administered in 167 patients followed by surgical resection with total mesorectal excision (TME). Another 41 patients received postoperative RCT. TS levels and further clinicopathological parameters were assessed in univariate and multivariate analyses. Additionally, a TS gene polymorphism was analyzed with respect to the intratumoral protein levels. Low TS expression in pretreatment biopsies correlated with impaired patient survival (p = 0.015). Analysis of a 28-bp repeat revealed a correlation between the 3/ 3 genotype and high TS expression in pretherapeutic biopsies. In this study, a correlation of TS expression and grade of RCT-induced tumor regression was not found. Histopathological examination confirmed a complete tumor remission in 16 patients (9.6%). Analyses of the resection specimen indicated an unfavorable prognosis for patients with low intratumoral TS expression in case of detected lymph node metastases (p = 0.04). TS can serve as a prognostic biomarker indicating an unfavorable prognosis for patients with low TS expression."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft [KFO 179]"],["dc.identifier.doi","10.1245/s10434-011-1608-4"],["dc.identifier.isi","000294346700008"],["dc.identifier.pmid","21347782"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7591"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22225"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1068-9265"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]